vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the U.S. Food and Drug
vTv Therapeutics got special FDA approval to develop a new medicine for sickle cell disease. This label means fewer rules and faster progress, so watch if their testing goes smoothly.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.